Instrument Inactif

Autres langues Teva Pharmaceutical Industries Limited NYSE

Actions

TEVA

US8816242098

Produits pharmaceutiques

Temps Différé NYSE 22:00:03 11/09/2026			Varia. 5j.	Varia. 1 janv.
37,09 ^USD	+2,04%		+0,65%	+18,84%

18/09	Teva Pharmaceuticals présente de nouvelles données post hoc sur l'olanzapine LAI TEV-749 soulignant des taux élevés de stabilisation et une efficacité à long terme en injection sous-cutanée mensuelle pour le traitement de la schizophrénie chez l'adulte	CI
10/02/21	Teva essuie une lourde perte en 2020	AW

Autres langues

02/10	Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates
02/10	Samsung Bioepis Signs Partnership Agreement with Teva for Two Biosimilar Candidates
01/10	Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
01/10	Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates
30/09	TAPI (Technology & API Services) Announces Appointment of Serge Rogasik as Chief Executive Officer
29/09	Afternoon Meeting: La renta variable desafía la presión
29/09	Aktien trotzen dem Druck
29/09	Stocks Defy the Pressure
29/09	Morning Meeting: Los bonos elevan la presión
29/09	Morning Meeting: Anleihen erhöhen den Druck
29/09	Bonds Turn Up the Pressure
28/09	Teva Pharmaceuticals Gets FDA Approval for Bone Drug as Biosimilar
28/09	Teva Reports FDA Approval for Degevma
28/09	Teva Pharmaceutical Industries Ltd. Receives U.S. FDA Approval Of DEGEVMA (Denosumab-Adet) As A Biosimilar To Xgeva
28/09	Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says
23/09	Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says
22/09	Teva Pharmaceutical Industries Insider Sold Shares Worth $285,215, According to a Recent SEC Filing
22/09	Teva Pharmaceutical Industries Insider Sold Shares Worth $14,356,802, According to a Recent SEC Filing
21/09	Medincell Partner Teva Presents New Data On Investigational Olanzapine LAI And UZEDY At Psych Congress 2026
18/09	Teva Pharmaceuticals Presents New Olanzapine Lai Tev-749 Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
11/06/20	EU-Gericht klärt Rechtsstreit zwischen Novartis und Ratiopharm
21/10/19	Pharmariesen wenden Schmerzmittel-Prozess durch Vergleich ab